Cargando…

Dosimetric comparison of robust angles in carbon-ion radiation therapy for prostate cancer

The objective of this study is to compare the plan robustness at various beam angles. Hence, the influence of the beam angles on robustness and linear energy transfer (LET) was evaluated in gantry-based carbon-ion radiation therapy (CIRT) for prostate cancer. 10 patients with prostate cancer were co...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Han-Back, Kim, Changhwan, Han, Min Cheol, Hong, Chae-Seon, Park, Seyjoon, Koom, Woong Sub, Kim, Jin Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978491/
https://www.ncbi.nlm.nih.gov/pubmed/36874141
http://dx.doi.org/10.3389/fonc.2023.1054693
Descripción
Sumario:The objective of this study is to compare the plan robustness at various beam angles. Hence, the influence of the beam angles on robustness and linear energy transfer (LET) was evaluated in gantry-based carbon-ion radiation therapy (CIRT) for prostate cancer. 10 patients with prostate cancer were considered, and a total dose of 51.6 Gy (Relative biological effectiveness (RBE) was prescribed for the target volume in 12 fractions. Five beam field plans comprising two opposed fields with different angle pairs were characterized. Further, dose parameters were extracted, and the RBE-weighted dose and LET values for all angle pairs were compared. All plans considering the setup uncertainty satisfied the dose regimen. When a parallel beam pair was used for perturbed scenarios to take into account set-up uncertainty in the anterior direction, the LET clinical treatment volume (CTV) D (95%) standard deviation was 1.5 times higher, and the standard deviation of RBE-weighted CTV D (95%) was 7.9 times higher compared to an oblique pair. The oblique beam fields were superior in terms of dose sparing for the rectum compared to the dose distribution using two conventional lateral opposed fields for prostate cancer.